Ultragenyx Pharmaceuticals Inc. laid the groundwork for a public exit by raising $75 million from a syndicate heavily represented by crossover investors who like the company's Orphan story and prospects for a near-term IPO.

CFO Shalini Sharp said Ultragenyx had several goals in mind when it began meeting with investors over the summer to drum up support for last week's series B round.